What is the equity of Allovir this year?
Allovir has equity of 145.78 M USD this year.
Allovir Equity 2024
Allovir Equity
145.78 M USD
Ticker
ALVR
ISIN
US0198181036
WKN
A2QAMR
In 2024, Allovir's equity was 145.78 M USD, a -35.06% increase from the 224.5 M USD equity in the previous year.
Allovir Aktienanalyse
What does Allovir do?
Allovir Inc was founded in 2013 in Cambridge, Massachusetts and is a biopharmaceutical company specializing in the development and commercialization of cellular immunotherapies for viral infections. The idea behind the founding of Allovir was to develop a new generation of immunotherapies with the potential to treat virus-related diseases that were previously difficult to treat. Allovir's business model is based on the development and commercialization of cellular immunotherapies that rely on the patient's immune system to fight infections. The company focuses on two main areas: infectious diseases and cancer. Within these areas, Allovir focuses on the development of therapies for severe viral infections such as BK virus, cytomegalovirus (CMV), and adenovirus, as well as the development of therapies to combat cancer. Allovir's first product candidates are Viral Associated Diseases (VAD) cell therapies developed to treat infections caused by BK virus, CMV, and adenovirus. These therapies consist of virus-specific T cells that are extracted from the patient's blood, amplified and activated in the laboratory, and then reintroduced into the patient where they can directly attack and eliminate the virus. Another promising product that Allovir is currently developing is ALVR106, a cellular immunotherapy for the treatment of cancer. ALVR106 is a CAR-T cell therapy candidate that aims to target HER2-positive solid tumors. The active ingredient is based on certain T cells that have been modified to specifically recognize and attack tumor-specific antigens. Allovir has conducted several successful clinical trials in recent years and has achieved promising results. Significant progress was observed in a clinical trial for the treatment of BK virus infections in kidney transplant patients. Therapy with virus-specific T cells resulted in a significant reduction in viral load and improvement in kidney function. Allovir's therapy also showed promising results in a Phase 2 trial for the treatment of CMV in bone marrow transplant patients. Allovir has established a strong position in the field of cellular immunotherapies for viral infections in recent years. The company has built an impressive research and development platform and has an experienced team of researchers and developers. The clinical results of Allovir's products demonstrate a high potential for future developments, and the company is expected to continue to grow and innovate in the coming years. Allovir ist eines der beliebtesten Unternehmen auf Eulerpool.com.Equity Details
Analyzing Allovir's Equity
Allovir's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Allovir's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating Allovir's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
Allovir's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in Allovir’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about Allovir stock
What was the equity of Allovir compared to the previous year?
The equity of Allovir has increased/decreased by -35.06% decreased compared to the previous year.
What impact does a high equity have on investors of Allovir?
A high equity is advantageous for investors of Allovir as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of Allovir?
A low equity can be a risk for investors of Allovir, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of Allovir affect the company?
An increase in equity of Allovir can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of Allovir affect the company?
A reduction in equity of Allovir can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of Allovir?
Some factors that can affect the equity of Allovir include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of Allovir so important for investors?
The equity of Allovir is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can Allovir take to change the equity?
To change equity, Allovir can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does Allovir pay?
Over the past 12 months, Allovir paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Allovir is expected to pay a dividend of 0 USD.
What is the dividend yield of Allovir?
The current dividend yield of Allovir is .
When does Allovir pay dividends?
Allovir pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Allovir?
Allovir paid dividends every year for the past 0 years.
What is the dividend of Allovir?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Allovir located?
Allovir is assigned to the 'Health' sector.
Wann musste ich die Aktien von Allovir kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Allovir from 10/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/1/2024.
When did Allovir pay the last dividend?
The last dividend was paid out on 10/1/2024.
What was the dividend of Allovir in the year 2023?
In the year 2023, Allovir distributed 0 USD as dividends.
In which currency does Allovir pay out the dividend?
The dividends of Allovir are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Allovir
Our stock analysis for Allovir Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Allovir Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
